These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2122654)

  • 1. Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
    Chouza C; Aljanati R; Caamaño JL; De Medina O; Scaramelli A; Buzó R; Plachín V; Fernandez A; Romero S
    Adv Neurol; 1990; 53():519-26. PubMed ID: 2122654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Madopar HBS in nocturnal symptoms of Parkinson's disease.
    Jansen EN; Meerwaldtt JD
    Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
    Chouza C; Romero S; de Medina O; Aljanati R; Scarmelli A; Caamano JL; Gonzales Panizza V
    Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH; Lees AJ; Stern GM
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
    Lees AJ
    Adv Neurol; 1990; 53():475-82. PubMed ID: 2239487
    [No Abstract]   [Full Text] [Related]  

  • 10. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F; Chaná P
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
    Chouza C; Caamaño JL; de Medina O; Aljanati R; Scaramelli A; Romero S
    J Neural Transm Suppl; 1988; 27():61-70. PubMed ID: 3042913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
    Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
    Dupont E; Andersen A; Boas J; Boisen E; Borgmann R; Helgetveit AC; Kjaer MO; Kristensen TN; Mikkelsen B; Pakkenberg H; Presthus J; Stien R; Worm-Petersen J; Buch D
    Acta Neurol Scand; 1996 Jan; 93(1):14-20. PubMed ID: 8825266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
    Bergemann N; Baas H; Fischer PA
    Nervenarzt; 1994 Apr; 65(4):250-7. PubMed ID: 8015632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
    Pacchetti C; Martignoni E; Sibilla L; Bruggi P; Turla M; Nappi G
    Eur Neurol; 1990; 30(6):319-23. PubMed ID: 2289507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.